

Resource Summary Report

Generated by NIF on Jul 28, 2026

APC anti-human CD8

RRID:AB_2075388

Type: Antibody

Proper Citation

BioLegend Cat# 344722, RRID:AB_2075388

Antibody Information

URL: http://antibodyregistry.org/AB_2075388

Proper Citation: BioLegend Cat# 344722, RRID:AB_2075388

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2075388

Vendor: BioLegend

Catalog Number: 344722

Alternative Catalog Numbers: 344721

Record Creation Time: 20250820T043836+0000

Record Last Update: 20250820T193221+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD8.

No alerts have been found for APC anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zhao Z, et al. (2025) Sick cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity. *Immunity*, 58(6), 1484.

Zhong L, et al. (2025) Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. *Cell*, 188(4), 1119.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. *Cell*, 188(14), 3823.

Newsome RC, et al. (2025) Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer. *Cell reports. Medicine*, 102519.

Chen L, et al. (2025) CD94/NKG2A-Qa-1b axis as a key modulator of vaccine responsiveness in aging populations. *Cell reports*, 44(11), 116514.

Hargarten JC, et al. (2025) Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome. *Science advances*, 11(12), eadi9885.

Matsushima R, et al. (2025) Imaging of biphasic signalosomes constructed by checkpoint receptor 2B4 in conventional and chimeric antigen receptor-T cells. *iScience*, 28(1), 111669.

Gu C, et al. (2025) An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery. *Cell reports. Medicine*, 102515.

Yin S, et al. (2024) Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer. *Cell stem cell*, 31(5), 717.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. *Cancer cell*.

Li Y, et al. (2024) SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. *Science translational medicine*, 16(731), eadk1599.

Aoki H, et al. (2024) CD8+ T cell memory induced by successive SARS-CoV-2 mRNA vaccinations is characterized by shifts in clonal dominance. *Cell reports*, 43(3), 113887.

Ursch LT, et al. (2024) Modulation of TCR stimulation and pifithrin- α improve the genomic safety profile of CRISPR-engineered human T cells. *Cell reports. Medicine*, 5(12), 101846.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. *Clinical and experimental immunology*.

Xu F, et al. (2023) Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8+ T cell. *Cell reports*, 42(11), 113424.

Vallet N, et al. (2023) Circulating T cell profiles associate with enterotype signatures underlying hematological malignancy relapses. *Cell host & microbe*, 31(8), 1386.

Cheng Y, et al. (2023) High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. *Cell reports. Medicine*, 4(10), 101214.

Oner A, et al. (2022) Transwell migration assay to interrogate human CAR-T cell chemotaxis. *STAR protocols*, 3(4), 101708.

Chen W, et al. (2022) Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy. *Cell reports*, 41(7), 111647.

Mudd PA, et al. (2022) SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. *Cell*, 185(4), 603.